UPenn Spin-Out VGX Licenses DNA Vaccine Tech From School in 'Ongoing Relationship' | GenomeWeb
VGX Pharmaceuticals has licensed from the University of Pennsylvania a number of DNA plasmids and constructs in an effort to better compete in the “burgeoning” DNA-based vaccine and therapy field, a VGX executive said last week.
 
The agreement, announced last week, is the latest in a number of licensing and sponsored research pacts between VGX and UPenn since the company spun out of the school in 2000, and underscores how long-term relationships between universities and spin-outs can benefit both parties.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.